---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-24-000162"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:25:57.110486+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q2 revenue up 32% to $6.6M; Nasdaq transfer due to bid price deficiency

## Summary
- Q2 revenue $6.6M (+32% YoY); net loss $12.6M ($0.29 loss per share) vs $14.0M loss a year ago.
- Gross margin improved 35pp vs Q2 2023; five Growth Direct systems placed; 150th system with top 15 pharma.
- Operational efficiency program: ~$7M annual savings; workforce reduction; aiming for positive cash flow by end-2027.
- Stock to transfer from Nasdaq Global Select to Nasdaq Capital Market on Aug 5 due to bid price <$1; 180-day compliance period.
- Reaffirms FY2024 revenue guidance >=$27M (>=20% growth) and at least 20 system placements.

## SEC filing metadata
- accession: 0001380106-24-000162
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000162/0001380106-24-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000162/rpid-20240802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-24-000162
- JSON: https://secwatch.observer/filing/0001380106-24-000162.json
- Plain text: https://secwatch.observer/filing/0001380106-24-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.